Implants

[WADDINGTON]

I just seen implants for amd is this true and is this nhs or private. Thanks

[Rosalyn-helpline Partner]

Dear Waddington,

Please ring us to discuss this further.

Kind regards,

Macular Society Advice and Information Service

0300 3030 111

[Hidden in reply to Rosalyn-helpline]

Hi I cannot call Brittan is there any information on this I can have?

[WADDINGTON in reply to Hidden]

Not sure seen on Google.

[Hidden in reply to Hidden]

Hi, found this on the mac soc website:

Implant means patients can go six months without injections

Thursday, 23 July, 2020 - 12:00

A study looking at the effectiveness of a small, refillable eye implant has shown that 98% of patients with wet age-related macular degeneration (AMD) were able to go six months between treatments.

Roche has announced positive results from its phase III Archway study, which has been evaluating the effectiveness of the Port Delivery System (PDS). It is the first wet AMD treatment to achieve positive phase III results for this long between treatments.

The PDS is slightly longer than a grain of rice and is surgically implanted in the eye. It is uniquely designed to continuously deliver a specialised formulation of Lucentis (the anti-VEGF medicine used to treat wet AMD) over time and be repeatedly refillable.

As well as reducing the number of treatments from as many as 12 per year to two per year for patients with wet AMD, the results show patients achieved similar vision outcomes to receiving monthly Lucentis injections.

Levi Garraway, Roche’s chief medical officer and head of global product development, said: “For over a decade, we have been working to develop new treatments that better address the unmet needs of people living with neovascular AMD,”

“Based on these data, we believe that the continuous delivery mechanism enabled by PDS may offer effective, reliable results while also alleviating the treatment burden. We are excited to share the data with regulatory authorities with the aim of bringing this new treatment option to patients as soon as possible.”

[springcross in reply to Hidden]

I wonder if the PDS would take Eylea if the Lucentis didn't work as well, as it doesn't with all patients.

[Hidden in reply to springcross]

Would've thought so in principle.

[Rosalyn-helpline Partner in reply to Hidden]

Hello Hollygg,

Are you able to email us?

[e-mail]

Kind regards,

[ALMD in reply to Rosalyn-helpline]

Why is the Macular Society reluctant to state openly that privately there are many treatments available which are not cost effective for the NHS. We have 2 systems in the UK and the choice should be available.

The Macular Society should be open and fully informative with its advice. It is not a political organisation.

[Rosalyn-helpline Partner in reply to ALMD]

Hello ALMD,

We are happy to provide information on all of the available treatments (or related research projects), both NHS and private. However, it is useful to know some more information from an individual in order to be able to provide applicable information. For instance, implants may or may not refer to lens implants. Lens implants of different types have been available for a number of years both on the NHS and privately e.g. the CentraSight telescopic implant, which is applicable to individuals with advanced dry AMD. It is a case of trying not to provide the incorrect information.

Kind regards.

Macular Society Advice and Information Service

0300 3030 111

[e-mail]

[Hidden]

Hi found this on the mac soc website:

Implant means patients can go six months without injections

Thursday, 23 July, 2020 - 12:00

A study looking at the effectiveness of a small, refillable eye implant has shown that 98% of patients with wet age-related macular degeneration (AMD) were able to go six months between treatments.

Roche has announced positive results from its phase III Archway study, which has been evaluating the effectiveness of the Port Delivery System (PDS). It is the first wet AMD treatment to achieve positive phase III results for this long between treatments.

The PDS is slightly longer than a grain of rice and is surgically implanted in the eye. It is uniquely designed to continuously deliver a specialised formulation of Lucentis (the anti-VEGF medicine used to treat wet AMD) over time and be repeatedly refillable.

As well as reducing the number of treatments from as many as 12 per year to two per year for patients with wet AMD, the results show patients achieved similar vision outcomes to receiving monthly Lucentis injections.

Levi Garraway, Roche’s chief medical officer and head of global product development, said: “For over a decade, we have been working to develop new treatments that better address the unmet needs of people living with neovascular AMD,”

“Based on these data, we believe that the continuous delivery mechanism enabled by PDS may offer effective, reliable results while also alleviating the treatment burden. We are excited to share the data with regulatory authorities with the aim of bringing this new treatment option to patients as soon as possible."